A5012642973- Eosinophilic Esophagitis
- Eosinophilic Disorders and Syndromes
- Esophageal and GI Pathology
- IL-33, ST2, and ILC Pathways
- Gastroesophageal reflux and treatments
- Esophageal Cancer Research and Treatment
- Gastrointestinal disorders and treatments
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Screening and Detection
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal Tumor Research and Treatment
- Foreign Body Medical Cases
- Microscopic Colitis
- HIV/AIDS drug development and treatment
- Inflammatory Bowel Disease
- HIV Research and Treatment
- Food Allergy and Anaphylaxis Research
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- HIV/AIDS Research and Interventions
- Dysphagia Assessment and Management
- Liver Disease and Transplantation
- Child Nutrition and Feeding Issues
- Adolescent and Pediatric Healthcare
- Organ Transplantation Techniques and Outcomes
University of North Carolina at Chapel Hill
2016-2025
Center for Digestive and Liver Diseases
2009-2024
University of North Carolina Health Care
2012-2024
Northwestern University
2024
Cincinnati Children's Hospital Medical Center
2024
Children's Hospital of Philadelphia
2024
Hospital General de Tomelloso
2024
Icahn School of Medicine at Mount Sinai
2024
University of Cincinnati
2024
Wake Forest University
2024
Esophageal eosinophilia and eosinophilic esophagitis (EoE) are increasingly recognized prevalent conditions, which now represent common clinical problems encountered by gastroenterologists, pathologists, allergists. The study of EoE has become a dynamic field with an evolving understanding the pathogenesis, diagnosis, treatment. Although there limited data supporting management decisions, parameters needed to guide care patients eosinophilic-esophageal disorders. In this evidence-based...
Background & AimsGastrointestinal (GI), liver, and pancreatic diseases are a source of substantial morbidity, mortality, cost in the United States. Quantification statistical analyses burden these important for researchers, clinicians, policy makers, public health professionals. We gathered data from national databases to estimate GI liver disease States.MethodsWe collected statistics on care utilization ambulatory inpatient setting along with cancers mortality 2007 through 2012. included...
Eosinophilic esophagitis (EoE) is an allergen-mediated inflammatory disease with no approved treatment in the United States. Dupilumab, a VelocImmune-derived human monoclonal antibody against interleukin (IL) 4 receptor, inhibits IL4 and IL13 signaling. Dupilumab effective of allergic, atopic, type 2 diseases, so we assessed its efficacy safety patients EoE.We performed phase study adults active EoE (2 episodes dysphagia/week peak esophageal eosinophil density 15 or more eosinophils per...
Consensus diagnostic recommendations to distinguish GORD from eosinophilic oesophagitis (EoE) by response a trial of proton pump inhibitors (PPIs) unexpectedly uncovered an entity called 'PPI-responsive oesophageal eosinophilia' (PPI-REE). PPI-REE refers patients with clinical and histological features EoE that remit PPI treatment. Recent evolving evidence, mostly adults, shows at baseline are clinically, endoscopically histologically indistinguishable have significant overlap in terms Th2...
Dupilumab, a fully human monoclonal antibody, blocks interleukin-4 and interleukin-13 signaling, which have key roles in eosinophilic esophagitis.
The desmosomal cadherin desmoglein-1 (DSG1) is an essential intercellular adhesion molecule that altered in various human cutaneous disorders; however, its regulation and function allergic disease remains unexplored. Herein, we demonstrate a specific reduction DSG1 esophageal biopsies from patients with eosinophilic esophagitis (EoE), emerging disorder characterized by chronic inflammation within the mucosa. Further, show gene silencing weakens epithelial integrity, induces cell separation...
ABSTRACT Objectives: Eosinophilic esophagitis (EoE) is becoming increasingly more common, but the prevalence of other eosinophilic gastrointestinal disorders (EGIDs) unknown. Our objective was to estimate gastritis, gastroenteritis, and colitis in United States. Methods: We used IMS Health LifeLink PharMetrics Plus Claims Database, data representative a US national commercially insured population containing medical pharmaceutical claims for >75 million individuals. restricted our sample...
A novel translational pharmacology investigation was conducted by combining an in vitro efficacy target with mucosal tissue pharmacokinetic (PK) data and mathematical modeling to determine the number of doses required for effective human immunodeficiency virus (HIV) preexposure prophylaxis (PrEP).
OBJECTIVES: Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is a newly recognized entity that must be differentiated from eosinophilic esophagitis (EoE). Little known about this condition. We aimed to determine the prevalence of PPI-REE and EoE in patients undergoing upper endoscopy features distinguish two groups. METHODS: This prospective study conducted at University North Carolina 2009 2011 enrolled consecutive adult outpatient endoscopy. Subjects had biopsies quantify...